Format

Send to

Choose Destination
Int J Mol Sci. 2010 Nov 17;11(11):4601-17. doi: 10.3390/ijms11114601.

Biomarker analysis of stored blood products: emphasis on pre-analytical issues.

Author information

1
Service RĂ©gional Vaudois de Transfusion Sanguine, route de la Corniche 2, CH-1066 Epalinges, Switzerland; E-Mails: julien.delobel@mavietonsang.ch (J.D.); olivier.rubin@mavietonsang.ch (O.R.); michel.prudent@mavietonsang.ch (M.P.); david.crettaz@mavietonsang.ch (D.C.); niels.lion@mavietonsang.ch (N.L.).

Abstract

Millions of blood products are transfused every year; many lives are thus directly concerned by transfusion. The three main labile blood products used in transfusion are erythrocyte concentrates, platelet concentrates and fresh frozen plasma. Each of these products has to be stored according to its particular components. However, during storage, modifications or degradation of those components may occur, and are known as storage lesions. Thus, biomarker discovery of in vivo blood aging as well as in vitro labile blood products storage lesions is of high interest for the transfusion medicine community. Pre-analytical issues are of major importance in analyzing the various blood products during storage conditions as well as according to various protocols that are currently used in blood banks for their preparations. This paper will review key elements that have to be taken into account in the context of proteomic-based biomarker discovery applied to blood banking.

KEYWORDS:

aging and storage lesions; biomarkers; labile blood products; pre-analytics; proteomics

PMID:
21151459
PMCID:
PMC3000103
DOI:
10.3390/ijms11114601
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center